Haemopoietic stem cell transplanation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

A.S. Moore, P.J. Shaw, A.R. Hallahan, Tina Carter, T. Kilo, I. Nivison-Smith, T.A. O'Brien, H. Tapp, L. Teague, S.R. Wilson, K. Tiedemann

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Objective: To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.Design, setting and participants: A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998–2006, with particular focus on the most recent years (2002–2006).Main outcome measures: Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.Results: Over the period 1998–2006, 522 autologous HSCT procedures (41%) and 737 allogeneic procedures (59%) were performed. About 60% of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34% of allogeneic transplants in 2006 using cord blood. Over the period 2002–2006, the median age of patients receiving transplants was 7 years (range, 0–19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33%) and acute myeloid leukaemia (24%). The most common indications for autologous HSCT were neuroblastoma (23%), medulloblastoma (21%) and Ewing sarcoma (10%). TRM at 1 year after transplant was 22% for alternative donor transplants, 7% for matched-sibling transplants and 5% for autologous transplants. Relapse or persistence of a child’s underlying condition accounted for 54% of all deaths within 1 year after transplant.Conclusions: HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.
    Original languageEnglish
    Pages (from-to)121-125
    JournalMedical Journal of Australia
    Volume190
    Issue number3
    Publication statusPublished - 2009

    Fingerprint

    Stem Cell Transplantation
    Hematology
    New Zealand
    Registries
    Stem Cells
    Bone Marrow
    Transplants
    Tissue Donors
    Fetal Blood
    Mortality
    Siblings
    Transplant Recipients
    Pediatrics
    Donor Selection
    Medulloblastoma
    Ewing's Sarcoma
    Autografts
    HLA Antigens
    Neuroblastoma
    Precursor Cell Lymphoblastic Leukemia-Lymphoma

    Cite this

    @article{313b7166e79e4a709d8a388284def527,
    title = "Haemopoietic stem cell transplanation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group",
    abstract = "Objective: To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.Design, setting and participants: A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998–2006, with particular focus on the most recent years (2002–2006).Main outcome measures: Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.Results: Over the period 1998–2006, 522 autologous HSCT procedures (41{\%}) and 737 allogeneic procedures (59{\%}) were performed. About 60{\%} of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34{\%} of allogeneic transplants in 2006 using cord blood. Over the period 2002–2006, the median age of patients receiving transplants was 7 years (range, 0–19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33{\%}) and acute myeloid leukaemia (24{\%}). The most common indications for autologous HSCT were neuroblastoma (23{\%}), medulloblastoma (21{\%}) and Ewing sarcoma (10{\%}). TRM at 1 year after transplant was 22{\%} for alternative donor transplants, 7{\%} for matched-sibling transplants and 5{\%} for autologous transplants. Relapse or persistence of a child’s underlying condition accounted for 54{\%} of all deaths within 1 year after transplant.Conclusions: HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.",
    author = "A.S. Moore and P.J. Shaw and A.R. Hallahan and Tina Carter and T. Kilo and I. Nivison-Smith and T.A. O'Brien and H. Tapp and L. Teague and S.R. Wilson and K. Tiedemann",
    year = "2009",
    language = "English",
    volume = "190",
    pages = "121--125",
    journal = "Medical Journal Australia",
    issn = "0025-729X",
    publisher = "Australasian Medical Publishing Co. Ltd",
    number = "3",

    }

    Haemopoietic stem cell transplanation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. / Moore, A.S.; Shaw, P.J.; Hallahan, A.R.; Carter, Tina; Kilo, T.; Nivison-Smith, I.; O'Brien, T.A.; Tapp, H.; Teague, L.; Wilson, S.R.; Tiedemann, K.

    In: Medical Journal of Australia, Vol. 190, No. 3, 2009, p. 121-125.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Haemopoietic stem cell transplanation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

    AU - Moore, A.S.

    AU - Shaw, P.J.

    AU - Hallahan, A.R.

    AU - Carter, Tina

    AU - Kilo, T.

    AU - Nivison-Smith, I.

    AU - O'Brien, T.A.

    AU - Tapp, H.

    AU - Teague, L.

    AU - Wilson, S.R.

    AU - Tiedemann, K.

    PY - 2009

    Y1 - 2009

    N2 - Objective: To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.Design, setting and participants: A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998–2006, with particular focus on the most recent years (2002–2006).Main outcome measures: Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.Results: Over the period 1998–2006, 522 autologous HSCT procedures (41%) and 737 allogeneic procedures (59%) were performed. About 60% of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34% of allogeneic transplants in 2006 using cord blood. Over the period 2002–2006, the median age of patients receiving transplants was 7 years (range, 0–19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33%) and acute myeloid leukaemia (24%). The most common indications for autologous HSCT were neuroblastoma (23%), medulloblastoma (21%) and Ewing sarcoma (10%). TRM at 1 year after transplant was 22% for alternative donor transplants, 7% for matched-sibling transplants and 5% for autologous transplants. Relapse or persistence of a child’s underlying condition accounted for 54% of all deaths within 1 year after transplant.Conclusions: HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.

    AB - Objective: To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.Design, setting and participants: A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998–2006, with particular focus on the most recent years (2002–2006).Main outcome measures: Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.Results: Over the period 1998–2006, 522 autologous HSCT procedures (41%) and 737 allogeneic procedures (59%) were performed. About 60% of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34% of allogeneic transplants in 2006 using cord blood. Over the period 2002–2006, the median age of patients receiving transplants was 7 years (range, 0–19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33%) and acute myeloid leukaemia (24%). The most common indications for autologous HSCT were neuroblastoma (23%), medulloblastoma (21%) and Ewing sarcoma (10%). TRM at 1 year after transplant was 22% for alternative donor transplants, 7% for matched-sibling transplants and 5% for autologous transplants. Relapse or persistence of a child’s underlying condition accounted for 54% of all deaths within 1 year after transplant.Conclusions: HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.

    M3 - Article

    VL - 190

    SP - 121

    EP - 125

    JO - Medical Journal Australia

    JF - Medical Journal Australia

    SN - 0025-729X

    IS - 3

    ER -